Medtronic (MDT) Granted 510(k) Clearance by FDA for LUCAS(TM) 2
More News related to MDT
- Medtronic (MDT) Appoints Michael Coyle to EVP and Group President of Cardiology Business
- Medtronic Names Michael J. Coyle as Executive Vice President and Group President of Cardiology Businesses
- Association's Campaign Inspires Teens to Use CPR, AEDs to Save Lives
- Medtronic CEO William Hawkins to Speak at 21st Annual Piper Jaffray Healthcare Conference
- Highlights From MDT's Q3 Conference Call: U.S. Revenues up 5%, International Sales Up 13%; Guides Above for FY10
More News related to FDA
- Cramer Tries His Best to Top-Tick Amazon (AMZN), Sets Street High $210 Price Target
- Despite Novartis Denial, UBS Makes A Strong Case That They Should Buy Alcon (ACL)
- JPMorgan (JPM) Could See $3B Revenues Hit On Derivatives Rules
- Goldman Issues 'Top Trades of 2010': Sees 2010, 2011 'Rather Strong Years', Gives Global, US, Euro, BRIC GDP Estimates
- More Thoughts On Apple's (AAPL) Quick Sell-Off Yesterday
Physio-Control Inc., a wholly-owned subsidiary of Medtronic, Inc. (NYSE: MDT), announced today that LUCAS(TM) 2, the next-generation LUCAS(TM) Chest Compression System, has been granted 510(k) market clearance by the U.S. FDA. Developed and manufactured by Jolife AB and distributed exclusively in the United States by Physio-Control, the LUCAS 2 is an automated, battery-powered device that is designed to give consistent, uninterrupted compressions to victims in cardiac arrest.
More from the release.
Related Categories
FDAStocks Mentioned
+0.93Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
